Anaphylaxis: Systemic IgE-Mediated Immune Collapse

Anaphylaxis is a severe, rapid-onset systemic hypersensitivity reaction that can be life-threatening. It represents the most extreme manifestation of Type I hypersensitivity, in which immune activation becomes widespread and uncontrolled. Rather than remaining localised, immune mediator release affects multiple organ systems simultaneously. The resulting physiological changes can progress within minutes and lead to airway compromise, circulatory collapse, and death.

What You Need to Know

Anaphylaxis is a rapidly evolving, systemic hypersensitivity reaction driven by IgE-mediated activation of mast cells and basophils. During initial exposure to an antigen, sensitisation occurs as antigen-specific IgE antibodies bind to high-affinity receptors on these cells. On re-exposure, antigen cross-linking of surface-bound IgE triggers immediate cellular activation and degranulation. Large quantities of pre-formed mediators such as histamine, along with newly synthesised mediators including leukotrienes and prostaglandins, are released directly into the circulation.

Several core mechanisms explain why anaphylaxis is abrupt, severe, and life-threatening:

• widespread vasodilation and increased vascular permeability leading to rapid intravascular volume loss

• smooth muscle contraction affecting the airways and gastrointestinal tract

• simultaneous involvement of multiple organ systems rather than a single target tissue

Because mediator release is immediate and systemic, the physiological effects occur within minutes and escalate quickly. Vasodilation and capillary leak reduce venous return and cardiac output, while bronchoconstriction and mucosal oedema impair ventilation. Gastrointestinal smooth muscle activation contributes to cramping and vomiting, and cutaneous vasodilation produces flushing and urticaria. These changes occur in parallel rather than sequence, which explains why cardiovascular collapse, airway compromise, and gastrointestinal symptoms may develop together.

Anaphylaxis severity is determined by the extent of mediator release and the body’s ability to compensate, not by the amount of antigen alone. Prior sensitisation lowers the activation threshold, meaning even minimal exposure can trigger profound physiological disruption. Anaphylaxis is therefore best understood as immune-driven circulatory and respiratory collapse caused by loss of vascular tone, fluid redistribution, and airway narrowing, rather than as an exaggerated local allergic reaction.

Beyond the Basics

Mast cell degranulation and mediator release

The initiating event in anaphylaxis is extensive mast cell and basophil degranulation following IgE cross-linking. Pre-formed mediators such as histamine are released immediately, while newly synthesised mediators including leukotrienes, prostaglandins, and platelet-activating factor are generated within minutes. These substances act simultaneously on blood vessels, airway smooth muscle, mucosal surfaces, and the gastrointestinal tract. The scale and systemic distribution of mediator release distinguish anaphylaxis from localised or mild allergic reactions.

Vascular permeability and intravascular fluid loss

Inflammatory mediators markedly increase vascular permeability across the systemic circulation. Plasma rapidly shifts from the intravascular space into interstitial tissues, producing acute intravascular volume depletion without external fluid loss. Effective circulating volume falls abruptly, reducing venous return and compromising tissue perfusion. This mechanism explains why hypotension can develop early and progress quickly, even in previously healthy individuals.

Loss of vascular tone and maldistribution of blood flow

In parallel with capillary leak, widespread vasodilation reduces systemic vascular resistance. Blood pools within the peripheral and splanchnic circulations rather than being distributed to the heart and brain. The combined effects of reduced preload and diminished vascular tone impair cardiac output, producing a shock state driven by immune mediator effects rather than primary cardiac or fluid pathology.

Airway and respiratory involvement

Anaphylaxis affects the respiratory system through multiple mechanisms. Bronchial smooth muscle contraction narrows the lower airways, while mucosal oedema and increased mucus secretion further increase airflow resistance. In the upper airway, tissue swelling can progress rapidly and compromise patency. Respiratory deterioration may occur independently of blood pressure changes, meaning airway failure can precede or occur without overt circulatory collapse.

Systemic progression and escalation

Once mediator release becomes widespread, anaphylaxis can escalate rapidly through positive feedback mechanisms. Ongoing immune activation amplifies vascular leak, airway narrowing, and hypotension, reducing oxygen delivery at both tissue and cellular levels. Without prompt interruption of this process, hypoxia and organ dysfunction develop quickly. The speed and simultaneity of these changes explain why early recognition and immediate intervention are central to survival, even when initial symptoms appear mild.

Clinical Connections

Anaphylaxis presents with variable combinations of cutaneous, respiratory, cardiovascular, and gastrointestinal features, and absence of one system does not exclude the diagnosis. Skin signs such as urticaria or flushing may be minimal or absent, particularly in rapidly progressive or severe reactions. Early features often reflect mediator effects on vascular tone, airway calibre, and gastrointestinal smooth muscle rather than hypotension alone, which means significant physiological compromise can be present before classic signs appear.

Several clinical patterns indicate high risk of rapid escalation:

• sudden involvement of two or more organ systems after a likely exposure

• early respiratory symptoms such as throat tightness, wheeze, or voice change suggesting airway oedema

• gastrointestinal cramping or vomiting accompanied by light-headedness or tachycardia

Clinical deterioration in anaphylaxis is driven by speed and spread rather than initial severity. Blood pressure may be preserved early due to compensatory mechanisms, even while intravascular volume is falling and airway resistance is increasing. Worsening tachycardia, respiratory distress, altered voice, or reduced responsiveness indicate loss of compensation and impending collapse. Escalation is therefore guided by trajectory, with emphasis on rapid progression and multi-system involvement, rather than waiting for hypotension or full symptom expression before acting.

Anaphylaxis is a medical emergency that requires immediate treatment to reverse airway, breathing, and circulatory compromise, with management focused on rapid administration of adrenaline and supportive care. Initial management includes:

• Immediate IM adrenaline as first-line treatment (IV may be used in severe or refractory cases, typically in critical care settings)

• Calling for help and initiating an emergency response

• Positioning the patient appropriately, usually lying flat

• Providing high-flow oxygen

• Establishing IV access and administering fluids if hypotensive

• Repeating adrenaline if symptoms persist

• Giving adjunct medications such as antihistamines and corticosteroids

• Ongoing monitoring and preparation for airway management if required

Concept Check

1. What immune mechanism triggers anaphylaxis?

2. Why does anaphylaxis cause rapid intravascular volume depletion?

3. How does mast cell degranulation affect both airway and circulation?

4. Why can anaphylaxis progress faster than other hypersensitivity reactions?

5. How does anaphylaxis differ from distributive shock in primary cause?